Does Rallies show Form 4 insider transactions for LGND?

Yes. Rallies tracks LGND insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is LGND research on Rallies investment advice?

No. Rallies provides research, data, and educational context for LGND. It does not provide personalized investment advice.

LGND (Ligand Pharmaceuticals Inc.) Stock Analysis - Insider Trades

Ligand Pharmaceuticals Inc. (LGND) is a publicly traded Healthcare sector company. As of May 21, 2026, LGND trades at $217.75 with a market cap of $4.17B and a P/E ratio of 27.80. LGND moved +4.88% today. Year to date, LGND is +13.39%; over the trailing twelve months it is +107.54%. Its 52-week range spans $93.58 to $247.38. Analyst consensus is strong buy with an average price target of $279.71. Rallies surfaces LGND's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading LGND stock inside the company?

Recent LGND insider activity includes KOZARICH JOHN W sold 1.57K, KOZARICH JOHN W sold 459, KOZARICH JOHN W sold 80, KOZARICH JOHN W sold 1, and KOZARICH JOHN W sold 165. Rallies tracks insider transaction dates, shares, prices, and estimated values.

LGND Key Metrics

Key financial metrics for LGND
Metric	Value
Price	$217.75
Market Cap	$4.17B
P/E Ratio	27.80
EPS	$7.90
Dividend Yield	0.08%
52-Week High	$247.38
52-Week Low	$93.58
Volume	0
Avg Volume	0
Revenue (TTM)	$274.48M
Net Income	$153.56M
Gross Margin	0.00%

Recent LGND Insider Trades

KOZARICH JOHN W sold 1.57K (~$352.01K) on May 13, 2026.
KOZARICH JOHN W sold 459 (~$102.82K) on May 12, 2026.
KOZARICH JOHN W sold 80 (~$18.19K) on May 1, 2026.
KOZARICH JOHN W sold 1 (~$229.87) on May 1, 2026.
KOZARICH JOHN W sold 165 (~$38.26K) on May 1, 2026.

Latest LGND News

Ligand Sees 56% Royalty Surge, Reaffirms Guidance, Eyes XOMA Deal — May 7, 2026
Ligand to Acquire Xoma Royalty for $739M, Adds Seven Marketed Products — Apr 27, 2026
FDA Approves FILSPARI for FSGS After 46% Proteinuria Drop, Ligand to Earn 9% — Apr 14, 2026
Ligand Strengthens Business Development with Two New VP Hires and Portfolio Head Promotion — Mar 26, 2026
Ligand Pharmaceuticals Secures $244 Target, Projects 23% Royalty CAGR — Mar 11, 2026

LGND Analyst Consensus

7 analysts cover LGND: 0 strong buy, 7 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $279.71.

Common questions about LGND

Who is trading LGND stock inside the company?: Recent LGND insider activity includes KOZARICH JOHN W sold 1.57K, KOZARICH JOHN W sold 459, KOZARICH JOHN W sold 80, KOZARICH JOHN W sold 1, and KOZARICH JOHN W sold 165. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for LGND?: Yes. Rallies tracks LGND insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is LGND research on Rallies investment advice?: No. Rallies provides research, data, and educational context for LGND. It does not provide personalized investment advice.